Nanobiotix S.A.
NBTX•NASDAQ•Healthcare•Biotechnology

About Nanobiotix

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOLaurent Levy
Founded2003
IPO DateDecember 11, 2020
Employees108
CountryFrance
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyEUR - EUR
TypeStock

Contact Information

Websitewww.nanobiotix.com
Phone33 1 40 26 04 70
Address
60 rue de Wattignies Paris, 75012 France

Corporate Identifiers

CIK0001760854
CUSIP63009J107
ISINUS63009J1079
SIC2834

Leadership Team & Key Executives

Laurent Levy Ph.D.
Co-Founder, President of the Executive Board and Chief Executive Officer
Bart Van Rhijn
Chief Financial and Business Officer and Member of Executive Board
Anne-Juliette Hermant M.A.
Chief People Officer and Member of Executive Board
Dr. Louis Kayitalire M.D.
Chief Medical Officer and Member of Executive Board
Earl J. Bergey Ph.d.
Co-Founder
Brandon Owens
Vice President of Strategic Marketing and Corporate Communication
Margaret Galluzzi
Vice President and Global Head of Clinical Operations
Dr. Leonard A. Farber M.D.
Chief Clinical and Medical Affairs Officer and Chairman of the Scientific Advisory Board